

KEY HIGHLIGHTS

August 1, 2017

Revance Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics

May 18, 2017

Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial

COMPANY BASICS

Headquarters

Revance Therapeutics, Inc.
7555 Gateway Boulevard
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400

Employees: 126*

Website: www.revance.com

Stock Symbol: RVNC

Stock Exchange: NASDAQ

Shares Outstanding: 30.8 million**

Market Cap: ~\$700 million

Key Contacts

Investor Relations:

Jeanie Herbert

714-325-3584

jherbert@revance.com

Burns McClellan

Ami Bavishi

212-213-0006

abavishi@burnsmc.com

Trade Media:

Nadine Tosk

(847) 920-9858

nadinepr@gmail.com

Transfer Agent

Computershare

+1 (877) 373 6374 (US, Canada, Puerto Rico)

+1 (781) 575 3120 (non-US)

For requests by email:

web.queries@computershare.com


ADVANCING A LONG-LASTING, NEXT GENERATION NEUROMODULATOR

ABOUT REVANCE THERAPEUTICS, INC.

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revance's science is based upon a proprietary peptide technology, which when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, musculoskeletal conditions and muscle movement disorders. The \$3.7 billion global neurotoxin market where Revance plans to compete is estimated to grow to \$6.6 billion by 2022, and the company's drug product candidates are targeted to both infiltrate and expand the market.

The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in clinical development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It could be the first differentiated neuromodulator introduced in nearly 30 years and has the potential to provide increased response rates and extended duration.



The company is also developing a topically applied neurotoxin for aesthetic and therapeutic indications, DaxibotulinumtoxinA Topical Gel (RT001). Beyond botulinum toxin, Revance expects its proprietary peptide technology can be applied to a variety of other macromolecules—from over-the-counter beauty products to prescription drugs used daily to treat chronic diseases.

ADVANCING NEUROTOXIN PIPELINE

Botulinum Toxin is a "Pipeline within a Product"

REVANCE AESTHETICS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
RT002 Injectable for Glabellar (Frown) Lines	[Progress bar spanning all phases]			
New RT002 Injectable Indications	[Progress bar in Pre-clinical]			
RT001 Topical	[Progress bar in Pre-clinical]			

REVANCE THERAPEUTICS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
RT002 Injectable for Cervical Dystonia	[Progress bar spanning all phases]			
RT002 Injectable for Plantar Fasciitis	[Progress bar spanning all phases]			
New RT002 Injectable Adjacent Indications	[Progress bar in Pre-clinical]			

*As of June 30, 2017 **As of July 27, 2017

REMARKABLE SCIENCE CHANGES EVERYTHING™

REVANCE AESTHETICS

Revance is focusing on the largest segment within the facial aesthetics market, glabellar (frown) lines.



Deep facial muscles that form frown lines are approved for treatment by current injectable botulinum toxins and are estimated to represent a nearly \$1 billion global market opportunity. These marketed neurotoxins have shown duration of effect of approximately 3-4 months. In a Phase 2 trial, DaxibotulinumtoxinA for Injection (RT002) achieved a 6-month duration of effect. The company has initiated a Phase 3 clinical program using RT002 injectable for the treatment of frown lines and plans to release topline results in fourth quarter of 2017.

REVANCE THERAPEUTICS

The therapeutic segment of the global neurotoxin market was estimated to be \$1.8 billion in 2015, larger and faster-growing than aesthetics. Revance plans to build a significant therapeutics portfolio, initially addressing cervical dystonia and plantar fasciitis.



Cervical dystonia is a very painful and debilitating neurologic disorder affecting the neck and shoulder muscles. Treatment for cervical dystonia involves regular neurological intervention. The most commonly prescribed treatment for cervical dystonia is botulinum toxin type A, which can reduce the signs and symptoms of the affliction. In May 2017, the company released positive 24-week results from its Phase 2 dose-escalating trial using RT002 injectable for the treatment of cervical dystonia and plans to meet with regulatory authorities in the second half of 2017 to finalize design of our next studies.



Plantar fasciitis, the most common cause of heel pain, is triggered by inflammation of the connective tissue in the arch of the foot. The company has initiated a Phase 2 trial using RT002 injectable to reduce the signs and symptoms of plantar fasciitis. Results are expected in the fourth quarter of 2017.

RT001 TOPICAL

Revance plans to pursue indications for its DaxibotulinumtoxinA Topical Gel (RT001) where topical administration of botulinum toxin provides a meaningful advantage over injection. It is designed to provide treatment with no needles, no downtime, no bruising and no pain. RT001 topical is in preclinical development as a potential treatment for a number of aesthetic and therapeutic uses.

2017 FINANCIAL OUTLOOK (AS OF AUGUST 3, 2017)

The company had unaudited cash and investments of \$165.5 million at June 30, 2017. Cash burn for 2017 is expected to be in the range of \$102-\$112 million. The company expects its current cash and investments to fund operations into first quarter 2019.

SELL-SIDE COVERAGE

FIRM	ANALYST
Cantor Fitzgerald	Louise Chen
Cowen and Company	Ken Cacciatore
Piper Jaffray & Company	David Amsellem
SunTrust Robinson Humphrey, Inc.	John T. Boris
William Blair	Tim Lugo

BOARD OF DIRECTORS

Angus C. Russell
Chairman of the Board

Dan Browne
Co-Founder, President & CEO

Robert Byrnes
Experienced Medical Device & Biotechnology Executive

Ronald Eastman
Essex Woodlands Health Ventures

Phyllis Gardner, M.D.
Professor of Medicine,
Stanford University

Julian Gangolli
GW Pharmaceuticals Inc.

Philip Vickers, Ph.D.
Experienced Pharmaceutical
R & D Executive

MANAGEMENT TEAM

Dan Browne
Co-Founder, President & CEO

Lauren Silvernail
CFO & Chief Business Officer

Abhay Joshi, Ph.D.
Chief Operating Officer

Todd Zavodnick
Chief Commercial Officer and President,
Aesthetics & Therapeutics (as of 9/18/17)

Roman Rubio, M.D.
SVP, Clinical Development

Justin Ford
VP, Human Resources and
Head of People

Mukul Agarwal
VP, Business Development

Azita Nejad
VP, Quality and Validations

FORWARD-LOOKING STATEMENTS

This Investor Fact Sheet contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties are risks described in the "Risk Factors" section of the Form 10-Q filed August 4, 2017. These forward-looking statements speak only as of the date hereof. Revance disclaims any obligation to update these forward-looking statements.

"Revance Therapeutics", TransMTS®, "Remarkable Science Changes Everything", and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

© 2017 Revance Therapeutics, Inc.
All rights reserved.